These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22221409)

  • 1. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?
    Cattaneo M
    J Thromb Haemost; 2012 Mar; 10(3):327-36. PubMed ID: 22221409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of high platelet reactivity on treatment with clopidogrel.
    Cattaneo M
    Semin Thromb Hemost; 2012 Oct; 38(7):645-51. PubMed ID: 23034824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
    Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
    Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
    Smock KJ; Saunders PJ; Rodgers GM; Johari V
    Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.
    Sharma RK; Erickson SW; Sharma R; Voelker DJ; Reddy HK; Dod H; Marsh JD
    Vasc Health Risk Manag; 2013; 9():187-93. PubMed ID: 23662064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of laboratory monitoring in antiplatelet therapy.
    Cattaneo M
    Handb Exp Pharmacol; 2012; (210):471-94. PubMed ID: 22918743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.
    Hernandez-Suarez DF; Scott SA; Tomey MI; Melin K; Lopez-Candales A; Buckley CE; Duconge J
    Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):235-241. PubMed ID: 28675986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes and ADP Receptor Blocker Therapy.
    Samoš M; Fedor M; Kovář F; Mokáň M; Bolek T; Galajda P; Kubisz P; Mokáň M
    J Diabetes Res; 2016; 2016():6760710. PubMed ID: 26824047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
    Consuegra-Sánchez L; López-Palop R; Cano P; Carrillo P; Picó F; Villegas M; Sanchis J; Kaski JC
    J Thromb Haemost; 2013 Feb; 11(2):379-81. PubMed ID: 23253198
    [No Abstract]   [Full Text] [Related]  

  • 15. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
    Chirumamilla AP; Maehara A; Mintz GS; Mehran R; Kanwal S; Weisz G; Hassanin A; Hakim D; Guo N; Baber U; Pyo R; Moses JW; Fahy M; Kovacic JC; Dangas GD
    JACC Cardiovasc Imaging; 2012 May; 5(5):540-9. PubMed ID: 22595163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.